摘要
目的 探讨唑来磷酸联合^131 I治疗甲状腺癌骨转移伴骨质疏松的疗效和不良反应.方法 选取2006年1月～2013年1月100例甲状腺癌骨转移伴骨质疏松患者按随机数字表均分为两组.对照组予131I,研究组采用131I联合唑来磷酸治疗.治疗6个月后,观察两组疗效及不良反应等.结果 研究组骨密度、骨代谢指标、疼痛情况、生活体力状况、骨转移病灶等改善情况均优于对照组,差异有统计学意义（P＜0.05）.骨骼相关事件及不良反应发生率低于对照组,差异有统计学意义（P＜0.05）.结论 ^131 I联合唑来磷酸治疗甲状腺癌骨转移伴骨质疏松有较好的临床疗效,能有效缓解疼痛,提高骨密度和生活质量,降低骨转移病灶发生率,骨骼相关事件及不良反应发生率较低.
Objective To study the curative effect and side-effect of 131I plus combined with zoledronic acid in patients with metastatic bone of thyroid cancer bone metastases and with osteoporosis. Methods From Janurary 2006 to 2013 Janurary, 100 cases of thyroid cancer bone metastases with osteoporosis were divided into two groups according to the random number table. The control group were given the 131I only,while the research group used 131I combing with zole- dronic acid. After 6 months treatment, we observed the curative effect and adverse reaction in the two groups. Results The BMD, bone metabolism index, the pain, living condition,bone metastatic lesions in the research group were better than the control group. The differences were statistically significant （P 〈0.05）. The skeletal related events and the in- cidence of adverse reaction in the research group were lower than the control group. The differences were statistically significant（P 〈0.05）. Conclusion 131I Combining with zoledronic acid on metastatic bone of thyroid cancer bone metas- tases with osteoporosis has better clinical curative effect. The therapy can effectively relieve pain, improve the quality of daily life, and reduce the incidence of bone metastases lesions, skeletal related events and lower incidence of ad- verse reactions.
出处
《中国现代医生》
2014年第10期39-41,44,共4页
China Modern Doctor
基金
浙江省继续医学教育项目(2011-04-07-009)
